Navigation Links
In Kids, Genes May Affect Leukemia Treatment
Date:1/27/2009

Finding could help tailor therapy regimen to individuals, experts say

TUESDAY, Jan. 27 (HealthDay News) -- Genetic variations appear to affect the way children respond to treatment for lymphoblastic leukemia, researchers report.

Although about 80 percent of children suffering from this type of blood and bone marrow cancer are cured, some children do not respond to treatment. Now researchers think they know why.

"For the first time, we used a genome-wide strategy to interrogate over 500,000 variations in inherited DNA to find common gene variations called SNPs, or single nucleotide polymorphisms, that predicted response to chemotherapy," said lead researcher Mary V. Relling, who chairs the pharmaceutical department at St. Jude Children's Research Hospital in Memphis, Tenn.

Much of the emphasis in research on why chemotherapy works better on some people than others has focused on differences in the leukemia cells themselves, Relling noted.

"Our findings imply that the DNA patients inherit from their parents also explains why some patients respond to chemotherapy better than others," she said. "We also found some interesting genes that were previously under-appreciated and may provide new targets for new drug development."

The report is published in the Jan. 28 issue of the Journal of the American Medical Association.

For the study, Relling's team studied genetic variations in 487 children with lymphoblastic leukemia. Their goal was to find evidence of disease that persisted after treatment.

The researchers found 102 SNPs associated with minimal residual disease. "A high proportion of the gene variations were related to levels of the chemotherapy in blood and in leukemia cells; some were related to leukemia cell biology," Relling said.

An equal number, 21, were also associated with blood-related relapse and with the performance of antileukemic drugs. Overall, 61.7 percent of the SNPs were linked to early response, relapse risk or the performance of antileukemic drugs, the researchers found.

"Some of the gene variation is likely to cause differences among patients in how quickly their bodies rid themselves of the chemotherapy, and some of the variations are likely to penetrate through to the leukemia cells and have an influence on the inherent sensitivity of the leukemia cells to chemotherapy," Relling said.

Knowing the genetics of patients and knowing the genetics of their tumors are both important in designing effective treatments, she explained.

"When modern genomics is used to try to personalize medication regimens for cancer, we will need to consider the genetic variation that each patient has inherited, in addition to the genetic variation that is unique to the tumor cells," Relling said. "It will be necessary to continue to do genomic research in as many patients with cancer as possible in order to be able to apply these results in the future."

Dr. Barton Kamen, chief medical officer of the Leukemia & Lymphoma Society, noted that almost 20 percent of children treated for lymphoblastic leukemia suffer cognitive damage from chemotherapy.

"The problem is that the high cure rate of lymphoblastic leukemia still has a price," Kamen said. But knowing the genetic makeup of people and their disease, he said, might make it possible to make treatment less toxic by using lower doses for a shorter time.

In addition, knowing the genetic makeup of children with lymphoblastic leukemia "might point to the reasons for the failure of treatment so we can do something better for the 20 percent of the kids who are destined to fail," Kamen said.

More information

The U.S. National Cancer Institute has more on childhood leukemia.



SOURCES: Mary V. Relling, Pharm.D., chair, pharmaceutical sciences, St. Jude Children's Research Hospital, Memphis, Tenn.; Barton Kamen, M.D., Ph.D., chief medical officer, Leukemia & Lymphoma Society, White Plains, N.Y.; Jan. 28, 2009, Journal of the American Medical Association


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. House Acts to Protect Kids, Save Lives by Increasing Federal Tobacco Taxes
2. For Kids, the Flu Can Be Severe, Even Deadly
3. ethiKids, inc. Launches Website and Products to Address Declining Ethics in Children
4. Sleep Apnea Can Trouble Kids, Too
5. President Bush Should Protect Kids, Not Big Tobacco By Signing Bill to Increase Cigarette Tax, Fund SCHIP
6. Kids, How Do You Manage Your Asthma? The AAAAI and AAP announce 17th annual poster contest
7. Popular or Not? Your Genes May Help Decide
8. Common Genes Link Bipolar Disorder, Schizophrenia
9. UCSF Researchers Use New Tools to Move in on Cancer Susceptibility Genes
10. 9 Genes Are Linked to Alzheimers
11. What is the pathogenesis of C. jejuni-related disease?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
In Kids, Genes May Affect Leukemia Treatment
(Date:2/24/2017)... ... February 24, 2017 , ... With millions of Americans ... important that we all are aware of our options and are empowered with ... announce the launch of its newest edition of "Vision and Hearing" in USA ...
(Date:2/24/2017)... Viejo, CA (PRWEB) , ... February 24, 2017 , ... ... Final Cut Pro X . Users have total control over position, rotation, distortion, ... and more all within Final Cut Pro X. , With ProGlass Prism users are ...
(Date:2/24/2017)... ... February 24, 2017 , ... The International Association of Eating Disorders Professionals (iaedp) ... You See” body image mannequin art competition. Selected from 15 submissions from around the ... revealed at the 31st annual iaedp Symposium, March 22 – 26 in Las Vegas. ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... services, which specializes in thought leadership , media relations, social media, content ... services that will be powered through Act-On, an intuitive marketing automation platform. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... 23, 2017  The particle counters market is ... from USD 275.9 million in 2016, at a ... report: http://www.reportlinker.com/p04718602-summary/view-report.html The growing ... R&D, and growth in manufacturing industries in emerging ... for particle counters. On the other hand, technical ...
(Date:2/24/2017)... Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an oncology ... it has acquired exclusive worldwide rights to develop, ... HDAC inhibitor targeting hematological and solid tumors. ... 1 and 2 clinical trials of Abexinostat in ... have already been completed, demonstrating that Abexinostat is ...
(Date:2/23/2017)... , Feb. 23, 2017 Visiomed, ... and services since 1997, is changing the landscape ... technology providing patients with pro-active, custom-made solutions. Recognizing ... for instant and affordable healthcare without walls, Visiomed ... high-level devices developed with healthcare professionals that is ...
Breaking Medicine Technology: